TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01919255
Drug: Picolight + Coolprep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
Study: NCT01919255
Drug: Picolight + Clicolon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
Study: NCT00488761
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02724163
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A nitrogen mustard alkylating agent from the oxazaphosphorine group
Study: NCT02946788
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BPX-01 1 or 2% topical gel will be applied to face once daily
Study: NCT03118817
Drug: HM95573
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops
Study: NCT00169104
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
Study: NCT00055445
Drug: IdB 1016
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01726075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop per eye twice a day during 24 months
Study: NCT05088733
Drug: Yang Yin Fu Zheng Jie Du therapy
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Study: NCT02061748
Drug: Observational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective Chart Review
Study: NCT04006704
Drug: D/C/F/TAF FDC placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
Study: NCT01028404
Drug: NN1952
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
Study: NCT01028404
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
Study: NCT01028404
Drug: NN1952
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
Study: NCT00905424
Drug: Antidepressant + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
Study: NCT00595543
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
Study: NCT00595543
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
Study: NCT00595543
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
Study: NCT04229706
Drug: Xiang Ju Ru Pi Ning capsule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: xiangjurupining capsule,8 capsule,tid,3 months.
Study: NCT01852513
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00371813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
Study: NCT02539719
Drug: SC-003
Normalized name: tobramycin 0.003 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00520299
Drug: ADI PEG 20
Normalized name: PEG-20 stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
Study: NCT03749616
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
Study: NCT03749616
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
Study: NCT02929862
Drug: LYC-55716
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
Study: NCT04457011
Drug: High dose Susu Xiao'er Zhike Granules 1 bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
Study: NCT04457011
Drug: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
Study: NCT00278863
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05857410
Drug: Dexmetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmetomidine (H20183219) 0.4μg / (kg·min)；
Study: NCT01871077
Drug: PRO-156
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
Study: NCT02160548
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard management for OP poisoning
Study: NCT02160548
Drug: Standard care+ 2.5 mg Salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin respiratory solution 2.5 mg
Study: NCT02160548
Drug: Standard care+ 5 mg Salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin respiratory solution 5 mg
Study: NCT01204086
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
Study: NCT03789097
Drug: Flt3L
Approvals — FDA: no, EMA: no, PMDA: no
Description: an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
Study: NCT00108290
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03162185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group participants (n = 30) will receive a placebo for 7 days.
Study: NCT04577794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder and solvent for oral solution reconstituted prior to use.
Study: NCT00073450
Drug: Farnesyl Protein Transferase Inhibitor
Normalized name: farnesyl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01275443
Drug: 300mg TMC278LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg TMC278LA intramuscular injection
Study: NCT01275443
Drug: 150mg TMC278LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg TMC278LA intramuscular injection
Study: NCT01275443
Drug: 1200mg TMC278LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg TMC278LA intramuscular injection
Study: NCT04338477
Drug: Nephrosolid tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adminstration of drug
Study: NCT00647972
Drug: Zyprexa® Tablets 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, single dose fasting
Study: NCT00280592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
Study: NCT01689441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00823238
Drug: ceftazidime and tobramycin
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00823238
Drug: inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01345656
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
Study: NCT01345656
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
Study: NCT01345656
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 10 mg BAY94-8862 tablet for duration of 4 weeks
Study: NCT01345656
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
Study: NCT01345656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for duration of 4 weeks
Study: NCT01345656
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
Study: NCT03199950
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral 2dd (08.00am - 10.00pm)
Study: NCT01718613
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Study: NCT02916134
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics.
Study: NCT00661635
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
Study: NCT00661635
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
Study: NCT00661635
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
Study: NCT00069849
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01126684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily for six months
Study: NCT01721447
Drug: Optison echocardiography contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
Study: NCT01619878
Drug: Artemether-lumefantrine (COA566)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dispersible tablet taken orally twice a day during 3 days.
Study: NCT03518086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04639960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve weeks of placebo treatment.
Study: NCT04491136
Drug: ARNI
Normalized name: Arnica
DrugBank: Arnica montana flower (DB14343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
Study: NCT00002519
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03284853
Drug: GANFORT®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sterile ophthalmic solution
Study: NCT00235014
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet QD
Study: NCT04163185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken once upon the earliest onset of migraine pain.
Study: NCT04369664
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
Study: NCT02243436
Drug: Ara C
Normalized name: Toxocara cati Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous use, 2g/m2, day 5
Study: NCT00678132
Drug: AZD 2281
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00082511
Drug: Prasterone (GL701)
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study.
Study: NCT03540615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02024477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily for 12 weeks
Study: NCT03695198
Drug: LY3361237 - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3361237 administered SC
Study: NCT03695198
Drug: LY3361237 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3361237 administered IV
Study: NCT03695198
Drug: Placebo - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered SC
Study: NCT03695198
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered IV
Study: NCT03053115
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cases will take liothyronine drops in the morning and two hours after dinner
Study: NCT03053115
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controls will take placebo two hours after dinner
Study: NCT02534753
Drug: Ascor L 500® (Ascorbic Acid Injection, USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile, solution containing 500 mg ascorbic acid per mL
Study: NCT01475344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
Study: NCT00791102
Drug: Placebo for ASP-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
Study: NCT01026116
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 every-3-week for four cycles
Study: NCT00689520
Drug: acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
Study: NCT04225247
Drug: Single Bond Universal
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
Study: NCT04712500
Drug: AND017
Approvals — FDA: no, EMA: no, PMDA: no
Description: AND017 oral capsule
Study: NCT03456830
Drug: ALLN-177
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
Study: NCT03456830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
Study: NCT01039597
Drug: ORE1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules containing 300 mg of the active, study drug
Study: NCT01039597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT02228772
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard chemotherapy dosage and duration
Study: NCT00834847
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet
Study: NCT04297839
Drug: Control Group (heparin or continuous saline)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
Study: NCT03287375
Drug: PIPAC
Normalized name: Zagam Respipac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02669888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
Study: NCT00651300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
Study: NCT00470418
Drug: NIC5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: a natural product, found in many foods and plants with mild insulin sensitizing effects
Study: NCT00523692
Drug: depemedrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
Study: NCT00490919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal system (placebo) worn for 7 days
Study: NCT00470418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT03711825
Drug: LYN-057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
Study: NCT02228772
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard chemotherapy dosage and duration
Study: NCT02228772
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy dosage and duration
Study: NCT02228772
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy dosage and duration
Study: NCT03129360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepared in capsules to appear identical to levetiracetam.
Study: NCT01014052
Drug: QLT091001
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral QLT091001 administered once daily for 7 days
Study: NCT01955720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01951599
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
Study: NCT00545103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered Once Daily (QD)
Study: NCT00953940
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
Study: NCT01589263
Drug: onaBoNT-A + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo
Study: NCT03726125
Drug: LY3374849 - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03726125
Drug: LY3374849 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01388088
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg twice a day
Study: NCT01388088
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg twice a day